Adamis Pharmaceuticals Corporation (ADMP)

Etorro trading 970x250
Adamis Pharmaceuticals Corporation (ADMP) Logo

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company’s specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men’s and women’s health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California. Address: 11682 El Camino Real, San Diego, CA, United States, 92130

Adamis Pharmaceuticals Corporation News and around…

Latest news about Adamis Pharmaceuticals Corporation (ADMP) common stock and company :

12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Oct, 2021 FinancialContent

Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 18.27% to $5.76 during Tuesday's regular session. Redhill ...

Top Penny Stocks to Watch Making Big Moves Right Now
19 Oct, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
19 Oct, 2021 FinancialContent

Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market ...

ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today
18 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adamis Pharmaceuticals (ADMP) stock is getting a major boost on Monday thanks to a response from the U.S. Food and Drug Administration. The post ADMP Stock: The FDA News That Has Penny Stock Adamis Pharmaceuticals Rocketing Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

12 Health Care Stocks Moving In Monday's Intraday Session
18 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 ...

Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others
18 Oct, 2021 FinancialContent
Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval
18 Oct, 2021 Yahoo! Finance

Shares of Adamis Pharmaceuticals Corp. soared 20.4% on massive volume toward an eight-month high in premarket trading Monday, after the biopharmaceutical company said Zimhi, it's high-dose naloxone injection for the treatment for opioid overdose, has been approved by the Food and Drug Administration. Trading volume spiked to 32.8 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 2.0 million shares. "We are very ex

12 Health Care Stocks Moving In Monday's Pre-Market Session
18 Oct, 2021 FinancialContent

Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market ...

Adamis Pharma Stock Jumps as FDA Clears Opioid-Overdose Treatment
18 Oct, 2021 Yahoo! Finance

Drug overdoses are the leading cause of death for people under age 50 in the U.S. Adamis just got FDA approval for an opioid-overdose treatment.

Adamis Receives FDA Approval for ZIMHI
18 Oct, 2021 Yahoo! Finance

New High-Dose Naloxone Product for the Treatment of Opioid OverdoseSAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose. Naloxone is an opioid antagonist and is generally considered the drug of choice for imme

Ten stocks worth watching next week
16 Oct, 2021 FinancialContent
East Bay Parkinson's drug maker to be swallowed up in potential $450M deal
11 Oct, 2021 Yahoo! Finance

The acquisition, expected to close by the end of this year or early 2022, includes $400 million in upfront payments.

Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
04 Oct, 2021 Yahoo! Finance

Appointment of New Director with Significant Experience in Drug Development, Licensing and CommercializationSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Dr. De

Why a pill you take at home could change the direction of the pandemic
01 Oct, 2021 FinancialContent

Merck and Ridgeback Therapeutics Inc.'s promising oral antiviral could shift the direction of the pandemic by making it easier for people with COVID-19 to take a pill at home that can keep them from getting severely sick.

Interesting ADMP Put And Call Options For January 2024
14 Sep, 2021 FinancialContent

Investors in Adamis Pharmaceuticals Corp. (ADMP) saw new options begin trading this week, for the January 2024 expiration..

Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study
03 Sep, 2021 Yahoo! Finance

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.

Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing
02 Sep, 2021 FinancialContent

Adamis Pharmaceuticals Corporation(NASDAQ: ADMP)has initiated dosingin the Phase 2/3 trial for Tempol, an oral ...

Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
02 Sep, 2021 FinancialContent
Top Penny Stocks to Watch To Stay Ahead in September 2021
25 Aug, 2021 FinancialContent
Trending Reddit Penny Stocks You Need to Know About Now
24 Aug, 2021 FinancialContent
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
24 Aug, 2021 FinancialContent
Immunology Journal Publishes Data For Adamis' COVID-19 Candidate
24 Aug, 2021 FinancialContent

Adamis Pharmaceuticals Corporation(NASDAQ: ADMP) hasannounced Tempol data publicationin the peer-reviewed journal ...

Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
24 Aug, 2021 FinancialContent
Mid-Day Market Update: Macy's Jumps After Q2 Results; PharmaCyte Biotech Shares Drop
19 Aug, 2021 FinancialContent

Midway through trading Thursday, the Dow traded down 0.40% to 34,819.43 while the NASDAQ rose 0.07% to 14,535.52. The S&P also fell, ...

Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
19 Aug, 2021 FinancialContent

NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Adamis Announces Agreement to Sell Portion of US Compounding Business
04 Aug, 2021 FinancialContent

Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline

Adamis Announces Results of 2021 Annual Meeting of Stockholders
19 Jul, 2021 FinancialContent

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector of Election’s certified results from the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”), each of the Company’s nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Election’s report, stockholders approved all other proposals considered at the Annual Meeting, including the approval on an advisory basis of the compensation paid to named executive officers and the ratification on an advisory basis of the appointment of our registered public accounting firm BDO USA, LLP for 2021. The Board thanks the Adamis stockholders for their engagement and support.

Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
13 Jul, 2021 FinancialContent

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on July 16, 2021. In addition, the Board issued the following statement:

Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist
01 Jul, 2021 FinancialContent

Adamis Pharmaceuticals Corporation (ADMP) is a NASDAQ Common Stock listed in , ,

970x250